Source: International Congress 2017 – Update on community acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Mortensen (Simsbury, United States of America). Azithromycin is associated with improved survival in patients with healthcare-associated pneumonia. 472

Member's Comments

No comment yet.

Related content which might interest you: Obesity is associated with improved survival in community-acquired pneumonia Source: Eur Respir J 2013; 42: 180-187 Year: 2013 Obesity is associated with improved outcome in community-acquired pneumonia Source: Annual Congress 2012 - Prognosis and outcome of respiratory infections Year: 2012 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002 Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Long term survival and risk factors for gram-negative bacillary aetiology in patients with community-acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia Source: Eur Respir J 2009; 33: 394-400 Year: 2009 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Impact of nosocomial pneumonia on the outcome of mechanically-ventilated patients Source: Eur Respir J 2004; 24: Suppl. 48, 548s Year: 2004 Prediction of complications development and lethal outcome in patients with community-acquired pneumonia Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression Source: Eur Respir J 2012; 40: 1201-1210 Year: 2012 On improving assessment of in-hospital mortality and ICU admisison in community-acquired pneumonia patients by using the e-CURB Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome Year: 2012 Prediction of prognosis in healthcare-associated pneumonia Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome Year: 2012